Russia Has Reduced the Share of Imported Vaccines in its Market from 69% to 17%

30 July 2020

GMP News

The total share of imported vaccines in Russia contracted to 17% in 2019 from 69% in 2015, Chief Executive Officer of the Russian state-run corporation Rostec Sergei Chemezov said on July 28 at the meeting with President Vladimir Putin.

“The share of our medical products is also growing; it holds about 10% on the market in present. We have been actually close to zero just recently,” the top manager said. “The pharmaceutical function also demonstrates successes. The share of imported vaccines on the Russian market was managed to be reduced from 69% in 2015 to 17% [in 2019],” Chemezov noted.

Previously reported, that clinical trials of the coronavirus vaccine developed by Russia’s Vektor State Research Center of Virology and Biotechnology were officially launched.

“In accordance with a designated protocol, the clinical trial began with five volunteers. The first volunteer was vaccinated on July 27, the second one will receive vaccine on July 30, or after a 72-hour interval,” the statement reads.

The three other volunteers will be vaccinated after the same interval. “The health of the trial participants will be monitored in a facility. The first vaccinated person is feeling well,” the agency added.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more